Using the computational pharmacophore-based ANCHOR.QUERY platform a new scaffold was discovered. Potent compounds evolved inhibiting the protein-protein interaction p53-MDM2. An extensive SAR study was performed based on our four-point pharmacophore model, yielding derivatives with affinity to MDM2 in the nanomolar range. Their binding affinity with MDM2 was evaluated using both fluorescence polarization (FP) assay and 2D-NMR-HSQC experiments.</p
The protein–protein interaction of p53 and MDM2/X is a promising non genotoxic anticancer target. A ...
Reactivation of p53 by release of the functional protein from its inhibition by MDM2 provides an eff...
Reactivation of p53 by release of the functional protein from its inhibition by MDM2 provides an eff...
Using the computational pharmacophore-based ANCHOR.QUERY platform a new scaffold was discovered. Pot...
Using the computational pharmacophore-based ANCHOR.QUERY platform a new scaffold was discovered. Pot...
Using the computational pharmacophore-based ANCHOR.QUERY platform a new scaffold was discovered. Pot...
Using the computational pharmacophore-based ANCHOR.QUERY platform a new scaffold was discovered. Pot...
Using the computational pharmacophore-based ANCHOR.QUERY platform a new scaffold was discovered. Pot...
Intrinsically disordered proteins are an emerging class of proteins without a folded structure and c...
Intrinsically disordered proteins are an emerging class of proteins without a folded structure and c...
Intrinsically disordered proteins are an emerging class of proteins without a folded structure and c...
Intrinsically disordered proteins are an emerging class of proteins without a folded structure and c...
Intrinsically disordered proteins are an emerging class of proteins without a folded structure and c...
Intrinsically disordered proteins are an emerging class of proteins without a folded structure and c...
Reactivation of p53 by release of the functional protein from its inhibition by MDM2 provides an eff...
The protein–protein interaction of p53 and MDM2/X is a promising non genotoxic anticancer target. A ...
Reactivation of p53 by release of the functional protein from its inhibition by MDM2 provides an eff...
Reactivation of p53 by release of the functional protein from its inhibition by MDM2 provides an eff...
Using the computational pharmacophore-based ANCHOR.QUERY platform a new scaffold was discovered. Pot...
Using the computational pharmacophore-based ANCHOR.QUERY platform a new scaffold was discovered. Pot...
Using the computational pharmacophore-based ANCHOR.QUERY platform a new scaffold was discovered. Pot...
Using the computational pharmacophore-based ANCHOR.QUERY platform a new scaffold was discovered. Pot...
Using the computational pharmacophore-based ANCHOR.QUERY platform a new scaffold was discovered. Pot...
Intrinsically disordered proteins are an emerging class of proteins without a folded structure and c...
Intrinsically disordered proteins are an emerging class of proteins without a folded structure and c...
Intrinsically disordered proteins are an emerging class of proteins without a folded structure and c...
Intrinsically disordered proteins are an emerging class of proteins without a folded structure and c...
Intrinsically disordered proteins are an emerging class of proteins without a folded structure and c...
Intrinsically disordered proteins are an emerging class of proteins without a folded structure and c...
Reactivation of p53 by release of the functional protein from its inhibition by MDM2 provides an eff...
The protein–protein interaction of p53 and MDM2/X is a promising non genotoxic anticancer target. A ...
Reactivation of p53 by release of the functional protein from its inhibition by MDM2 provides an eff...
Reactivation of p53 by release of the functional protein from its inhibition by MDM2 provides an eff...